{
  "pmcid": "8135056",
  "sha256": "b8d90ab194294917ce21cf6896139c8ee8dc84d7d2a93bf965ef1b3cc25d7889",
  "timestamp_utc": "2025-11-10T00:08:30.564368+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 14.658596491228074,
    "reading_ease": 15.840789473684225,
    "word_count": 276
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Perioperative Systemic Therapy in Resectable Colorectal Peritoneal Metastases"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "open-label, parallel-group phase 2 randomised clinical trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "Eligible participants were patients with pathologically confirmed isolated resectable CPM who had not received systemic therapy within six months prior to enrollment."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomised to receive either perioperative systemic therapy or CRS-HIPEC alone."
      },
      "Objective": {
        "score": 1,
        "evidence": "To date, no randomised clinical trials have evaluated perioperative systemic therapy compared to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) alone for resectable colorectal peritoneal metastases (CPM)."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the proportion of macroscopic complete CRS-HIPEC and Clavien-Dindo grade 3 or higher postoperative morbidity."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was performed using a computer-generated sequence, and allocation was concealed."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Outcome assessors were blinded."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "A total of 79 patients were randomised, with 37 in the experimental arm and 42 in the control arm."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "The analysis was conducted on a modified intention-to-treat basis."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The proportions of macroscopic complete CRS-HIPEC were 89% in the experimental arm and 86% in the control arm (risk ratio, 1.04; 95% CI, 0.88-1.23; P = .74)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Clavien-Dindo grade 3 or higher morbidity was 22% in the experimental arm and 33% in the control arm (risk ratio, 0.65; 95% CI, 0.31-1.37; P = .25). No treatment-related deaths occurred."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "ClinicalTrials.gov Identifier: NCT02758951"
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 20,
    "max_score": 25
  }
}